商业-话题@MedSci

#商业#

128篇内容 | 2910人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1771829, encodeId=13321e718290d, content=<a href='/topic/show?id=62754005931' target=_blank style='color:#2F92EE;'>#商业#</a>, objectTitle=Alvotech就美国专利和商业秘密纠纷与AbbVie达成和解，Alvotech的拟议Humira®高浓度生物仿制药(AVT02)可在美国销售, objectType=article, longId=300761, objectId=3b82300e6134, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3b82300e6134, replyNumber=0, likeNumber=107, createdTime=2023-01-29, rootId=0, userName=zhangxingru, userId=fd6238344589, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3b82300e6134, moduleTitle=Alvotech就美国专利和商业秘密纠纷与AbbVie达成和解，Alvotech的拟议Humira®高浓度生物仿制药(AVT02)可在美国销售, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3b82300e6134)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1771828, encodeId=d74f1e71828b6, content=<a href='/topic/show?id=62754005931' target=_blank style='color:#2F92EE;'>#商业#</a>, objectTitle=生物技术行业领军人物为硕迪带来超过40年跨国制药和生物技术公司的商业和领导经验, objectType=article, longId=294453, objectId=525e294453c1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=525e294453c1, replyNumber=0, likeNumber=75, createdTime=2022-07-13, rootId=0, userName=zhangxingru, userId=fd6238344589, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=525e294453c1, moduleTitle=生物技术行业领军人物为硕迪带来超过40年跨国制药和生物技术公司的商业和领导经验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=525e294453c1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1771827, encodeId=edd61e7182768, content=<a href='/topic/show?id=62754005931' target=_blank style='color:#2F92EE;'>#商业#</a>, objectTitle=Aerogen®和康希诺生物就吸入给药新冠疫苗的开发和商业供货建立里程碑式的合作伙伴关系, objectType=article, longId=291853, objectId=fdf129185389, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fdf129185389, replyNumber=0, likeNumber=92, createdTime=2022-08-22, rootId=0, userName=zhangxingru, userId=fd6238344589, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fdf129185389, moduleTitle=Aerogen®和康希诺生物就吸入给药新冠疫苗的开发和商业供货建立里程碑式的合作伙伴关系, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fdf129185389)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1771826, encodeId=76c01e718268f, content=<a href='/topic/show?id=62754005931' target=_blank style='color:#2F92EE;'>#商业#</a>, objectTitle=武田与JCR Pharmaceuticals合作，将亨特综合征下一代治疗药物商业化, objectType=article, longId=218421, objectId=20732184217a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=20732184217a, replyNumber=0, likeNumber=88, createdTime=2022-01-01, rootId=0, userName=一叶知秋, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=20732184217a, moduleTitle=武田与JCR Pharmaceuticals合作，将亨特综合征下一代治疗药物商业化, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=20732184217a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1771823, encodeId=33f81e71823af, content=<a href='/topic/show?id=62754005931' target=_blank style='color:#2F92EE;'>#商业#</a>, objectTitle=Radiology：医疗保险和商业保险人群之间诊断成像使用率的比较：为什么重要？, objectType=article, longId=212441, objectId=486a21244194, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=486a21244194, replyNumber=0, likeNumber=79, createdTime=2022-03-30, rootId=0, userName=zhangxingru, userId=fd6238344589, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=486a21244194, moduleTitle=Radiology：医疗保险和商业保险人群之间诊断成像使用率的比较：为什么重要？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=486a21244194)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1771822, encodeId=4f061e71822b4, content=<a href='/topic/show?id=62754005931' target=_blank style='color:#2F92EE;'>#商业#</a>, objectTitle=2021年5月10日全球新冠肺炎（COVID-19）疫情简报，日新增63.3万，BioNtech mRNA新冠疫苗将在国内生产和商业化, objectType=article, longId=211060, objectId=0efc211060e6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0efc211060e6, replyNumber=0, likeNumber=87, createdTime=2021-06-05, rootId=0, userName=zhangxingru, userId=fd6238344589, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0efc211060e6, moduleTitle=2021年5月10日全球新冠肺炎（COVID-19）疫情简报，日新增63.3万，BioNtech mRNA新冠疫苗将在国内生产和商业化, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0efc211060e6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1771820, encodeId=517e1e718200e, content=<a href='/topic/show?id=62754005931' target=_blank style='color:#2F92EE;'>#商业#</a>, objectTitle=艾伯维指控Alvotech窃取修美乐商业机密, objectType=article, longId=209489, objectId=a3022094894b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a3022094894b, replyNumber=0, likeNumber=88, createdTime=2021-06-28, rootId=0, userName=zhangxingru, userId=fd6238344589, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a3022094894b, moduleTitle=艾伯维指控Alvotech窃取修美乐商业机密, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a3022094894b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1771824, encodeId=cca91e718240c, content=<a href='/topic/show?id=62754005931' target=_blank style='color:#2F92EE;'>#商业#</a>, objectTitle=和黄医药与美国Epizyme将开展表观遗传学药物的开发与商业化, objectType=article, longId=215484, objectId=c5ca215484fd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c5ca215484fd, replyNumber=0, likeNumber=121, createdTime=2021-12-06, rootId=0, userName=zhangxingru, userId=fd6238344589, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c5ca215484fd, moduleTitle=和黄医药与美国Epizyme将开展表观遗传学药物的开发与商业化, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c5ca215484fd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1771825, encodeId=aab11e718258b, content=<a href='/topic/show?id=62754005931' target=_blank style='color:#2F92EE;'>#商业#</a>, objectTitle=万春布林和恒瑞医药就普那布林在大中华区的商业化、临床开发及股权投资达成战略合作, objectType=article, longId=216366, objectId=36882163668a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=36882163668a, replyNumber=0, likeNumber=78, createdTime=2022-06-23, rootId=0, userName=zhangxingru, userId=fd6238344589, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=36882163668a, moduleTitle=万春布林和恒瑞医药就普那布林在大中华区的商业化、临床开发及股权投资达成战略合作, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=36882163668a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1771821, encodeId=39af1e7182185, content=<a href='/topic/show?id=62754005931' target=_blank style='color:#2F92EE;'>#商业#</a>, objectTitle=东曜药业：深度布局抗肿瘤ADC药物的研发及商业化, objectType=article, longId=209505, objectId=cd5120950549, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cd5120950549, replyNumber=0, likeNumber=70, createdTime=2021-06-03, rootId=0, userName=zhangxingru, userId=fd6238344589, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cd5120950549, moduleTitle=东曜药业：深度布局抗肿瘤ADC药物的研发及商业化, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cd5120950549)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1771819, encodeId=70291e71819c8, content=<a href='/topic/show?id=62754005931' target=_blank style='color:#2F92EE;'>#商业#</a>, objectTitle=中国创新药如何才能在美国取得商业成功, objectType=article, longId=202914, objectId=e8f4202914a5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e8f4202914a5, replyNumber=0, likeNumber=88, createdTime=2021-03-20, rootId=0, userName=zhangxingru, userId=fd6238344589, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e8f4202914a5, moduleTitle=中国创新药如何才能在美国取得商业成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e8f4202914a5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1771812, encodeId=baa71e71812b0, content=<a href='/topic/show?id=62754005931' target=_blank style='color:#2F92EE;'>#商业#</a>, objectTitle=Sci Rep：商业化阴道产品对尿路致病菌和阴道共生菌的影响 , objectType=article, longId=194834, objectId=0fc7194834a2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0fc7194834a2, replyNumber=0, likeNumber=88, createdTime=2020-07-27, rootId=0, userName=仁心济世, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0fc7194834a2, moduleTitle=Sci Rep：商业化阴道产品对尿路致病菌和阴道共生菌的影响 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0fc7194834a2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1771813, encodeId=44441e71813f8, content=<a href='/topic/show?id=62754005931' target=_blank style='color:#2F92EE;'>#商业#</a>, objectTitle=Clin Chem：使用两种商业测序平台对结核分枝杆菌培养物进行全面耐药性分析, objectType=article, longId=197769, objectId=23dc19e7699c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=23dc19e7699c, replyNumber=0, likeNumber=84, createdTime=2021-05-16, rootId=0, userName=zhangxingru, userId=fd6238344589, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=23dc19e7699c, moduleTitle=Clin Chem：使用两种商业测序平台对结核分枝杆菌培养物进行全面耐药性分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=23dc19e7699c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1771817, encodeId=40041e7181799, content=<a href='/topic/show?id=62754005931' target=_blank style='color:#2F92EE;'>#商业#</a>, objectTitle=技术没有大“惊艳”，但挡不住马斯克的脑机计划向商业化狂奔, objectType=article, longId=200585, objectId=04ad2005856e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=04ad2005856e, replyNumber=0, likeNumber=75, createdTime=2020-10-19, rootId=0, userName=zhangxingru, userId=fd6238344589, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=04ad2005856e, moduleTitle=技术没有大“惊艳”，但挡不住马斯克的脑机计划向商业化狂奔, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=04ad2005856e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1771814, encodeId=34361e71814ed, content=<a href='/topic/show?id=62754005931' target=_blank style='color:#2F92EE;'>#商业#</a>, objectTitle=医生多点执业，推动商业保险，中国医疗行业发展路得这么走, objectType=article, longId=198843, objectId=7e311988433e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7e311988433e, replyNumber=0, likeNumber=68, createdTime=2021-04-07, rootId=0, userName=zhangxingru, userId=fd6238344589, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7e311988433e, moduleTitle=医生多点执业，推动商业保险，中国医疗行业发展路得这么走, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7e311988433e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1771811, encodeId=4b741e718117c, content=<a href='/topic/show?id=62754005931' target=_blank style='color:#2F92EE;'>#商业#</a>, objectTitle=JAHA：商业引入经导管二尖瓣修复术对二尖瓣外科手术的影响, objectType=article, longId=191577, objectId=d9d41915e791, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d9d41915e791, replyNumber=0, likeNumber=93, createdTime=2020-12-14, rootId=0, userName=zhangxingru, userId=fd6238344589, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d9d41915e791, moduleTitle=JAHA：商业引入经导管二尖瓣修复术对二尖瓣外科手术的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d9d41915e791)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1771818, encodeId=57de1e71818aa, content=<a href='/topic/show?id=62754005931' target=_blank style='color:#2F92EE;'>#商业#</a>, objectTitle=辉瑞投资基石药业2亿美元，获得PD-L1大陆**商业权利, objectType=article, longId=201425, objectId=e5ba20142593, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e5ba20142593, replyNumber=0, likeNumber=75, createdTime=2020-11-13, rootId=0, userName=zhangxingru, userId=fd6238344589, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e5ba20142593, moduleTitle=辉瑞投资基石药业2亿美元，获得PD-L1大陆**商业权利, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e5ba20142593)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1771815, encodeId=d54a1e718159a, content=<a href='/topic/show?id=62754005931' target=_blank style='color:#2F92EE;'>#商业#</a>, objectTitle=刘士远：人才缺失、数据库建立与商业化是影响医学影像AI的三大要素, objectType=article, longId=200169, objectId=85b120016913, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=85b120016913, replyNumber=0, likeNumber=75, createdTime=2021-03-17, rootId=0, userName=zhangxingru, userId=fd6238344589, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=85b120016913, moduleTitle=刘士远：人才缺失、数据库建立与商业化是影响医学影像AI的三大要素, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=85b120016913)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1771807, encodeId=ddf91e71807db, content=<a href='/topic/show?id=62754005931' target=_blank style='color:#2F92EE;'>#商业#</a>, objectTitle=我国将积极发展社会服务领域商业保险, objectType=article, longId=185573, objectId=18d31855e39f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=18d31855e39f, replyNumber=0, likeNumber=77, createdTime=2020-08-15, rootId=0, userName=zhangxingru, userId=fd6238344589, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=18d31855e39f, moduleTitle=我国将积极发展社会服务领域商业保险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=18d31855e39f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1771810, encodeId=3ad31e71810ad, content=<a href='/topic/show?id=62754005931' target=_blank style='color:#2F92EE;'>#商业#</a>, objectTitle=CLIN CHEM LAB MED：双中心比较10个全自动商业降钙素原(PCT)免疫检测结果, objectType=article, longId=187936, objectId=a56618e936e2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a56618e936e2, replyNumber=0, likeNumber=71, createdTime=2020-08-05, rootId=0, userName=zhangxingru, userId=fd6238344589, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a56618e936e2, moduleTitle=CLIN CHEM LAB MED：双中心比较10个全自动商业降钙素原(PCT)免疫检测结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a56618e936e2)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

商业

2020-05-29

zhangxingru (审核中...)

前往app查看评论内容

#商业#

Alvotech就美国专利和商业秘密纠纷与AbbVie达成和解，Alvotech的拟议Humira®高浓度生物仿制药(AVT02)可在美国销售

2023-01-29

zhangxingru (审核中...)

前往app查看评论内容

#商业#

生物技术行业领军人物为硕迪带来超过40年跨国制药和生物技术公司的商业和领导经验

2022-07-13

zhangxingru (审核中...)

前往app查看评论内容

#商业#

Aerogen®和康希诺生物就吸入给药新冠疫苗的开发和商业供货建立里程碑式的合作伙伴关系

2022-08-22

一叶知秋 (审核中...)

前往app查看评论内容

#商业#

武田与JCR Pharmaceuticals合作，将亨特综合征下一代治疗药物商业化

2022-01-01

zhangxingru (审核中...)

前往app查看评论内容

#商业#

Radiology：医疗保险和商业保险人群之间诊断成像使用率的比较：为什么重要？

2022-03-30

zhangxingru (审核中...)

前往app查看评论内容

#商业#

2021年5月10日全球新冠肺炎（COVID-19）疫情简报，日新增63.3万，BioNtech mRNA新冠疫苗将在国内生产和商业化

2021-06-05

zhangxingru (审核中...)

前往app查看评论内容

#商业#

艾伯维指控Alvotech窃取修美乐商业机密

2021-06-28

zhangxingru (审核中...)

前往app查看评论内容

#商业#

和黄医药与美国Epizyme将开展表观遗传学药物的开发与商业化

2021-12-06

zhangxingru (审核中...)

前往app查看评论内容

#商业#

万春布林和恒瑞医药就普那布林在大中华区的商业化、临床开发及股权投资达成战略合作

2022-06-23

zhangxingru (审核中...)

前往app查看评论内容

#商业#

东曜药业：深度布局抗肿瘤ADC药物的研发及商业化

2021-06-03

zhangxingru (审核中...)

前往app查看评论内容

#商业#

中国创新药如何才能在美国取得商业成功

2021-03-20

仁心济世 (审核中...)

前往app查看评论内容

#商业#

Sci Rep：商业化阴道产品对尿路致病菌和阴道共生菌的影响

2020-07-27

zhangxingru (审核中...)

前往app查看评论内容

#商业#

Clin Chem：使用两种商业测序平台对结核分枝杆菌培养物进行全面耐药性分析

2021-05-16

zhangxingru (审核中...)

前往app查看评论内容

#商业#

技术没有大“惊艳”，但挡不住马斯克的脑机计划向商业化狂奔

2020-10-19

zhangxingru (审核中...)

前往app查看评论内容

#商业#

医生多点执业，推动商业保险，中国医疗行业发展路得这么走

2021-04-07

zhangxingru (审核中...)

前往app查看评论内容

#商业#

JAHA：商业引入经导管二尖瓣修复术对二尖瓣外科手术的影响

2020-12-14

zhangxingru (审核中...)

前往app查看评论内容

#商业#

辉瑞投资基石药业2亿美元，获得PD-L1大陆**商业权利

2020-11-13

zhangxingru (审核中...)

前往app查看评论内容

#商业#

刘士远：人才缺失、数据库建立与商业化是影响医学影像AI的三大要素

2021-03-17

zhangxingru (审核中...)

前往app查看评论内容

#商业#

我国将积极发展社会服务领域商业保险

2020-08-15

zhangxingru (审核中...)

前往app查看评论内容

#商业#

CLIN CHEM LAB MED：双中心比较10个全自动商业降钙素原(PCT)免疫检测结果

2020-08-05

科室
- - 订阅+
  - 更多科室
工具
服务